By accepting you will be accessing a service provided by a third-party external to

Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Antibodies | News Channels -|Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Antibodies | News Channels -|Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Antibodies | News Channels -

Details Hits: 97

The primary endpoint of the Phase 2 PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued

CAMBRIDGE, MA, USA I December 13, 2019 IToday, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear palsy (PSP). The primary endpoint, as measured by the PSP rating scale (PSPRS) at week 52, was not statistically significant. In addition, the study did not demonstrate efficacy on key clinical secondary endpoints. Based on these results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies.

“We are disappointed with the efficacy results of the Phase 2 PASSPORT study,” said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development and Chief Medical Officer at Biogen. “We remain unwavering in our commitment to advancing therapies that have the potential to address the significant unmet medical needs of people with neurodegenerative diseases who are faced with limited to no treatment options.”

Safety results of the PASSPORT study were generally consistent with previous studies of gosuranemab. Detailed results of this study will be made available in a future scientific forum.

Biogen will continue its ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD, given differences in disease pathology.

About Gosuranemab
Gosuranemab (BIIB092) is a humanized monoclonal antibody that targets N-terminal tau. Gosuranemab-mediated removal of N-terminal tau is being studied to evaluate whether it slows the progression of disease in tauopathies.

TANGO, a Phase 2 study, is designed to evaluate the safety and tolerability of gosuranemab in participants with mild cognitive impairment due to Alzheimer’s disease or with mild Alzheimer’s disease.

Biogen licensed gosuranemab from Bristol-Myers Squibb Company.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat Multiple Sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in Multiple Sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimer’s disease and dementia, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.

We routinely post information that may be important to investors on our website at To learn more, please visit and follow us on social media – TwitterLinkedInFacebookYouTube.

SOURCE: Biogen

Jamie-Lynn Sigler Opens Up About How Her Kids Reac...
Guest Op-ed: Who Makes Christmas? - Lynn Journal


No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Wednesday, 27 May 2020

Captcha Image RSS Statement

Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.